Organization
Research Institute for Radiation Biology and Medicine
3 abstracts
Abstract
Benefit of perioperative chemotherapy in the patients with loco-regional recurrence of HR-positive HER2-negative breast cancer: A multi-institutional retrospective cohort study.Org: Breast Medical Oncology Department, Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan, Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), Fukushima Medical University, School of Medicine, Department of Breast Oncology, Cancer Hospital of Xinjiang Medical University, Urumuqi, China, Research Institute for Radiation Biology and Medicine,
Abstract
Innovation of the first-line strategy optimized as abemaciclib with endocrine therapy based on the ESR1 mutation of ctDNA for patients with HR-positive HER2-negative advanced metastatic breast cancer (JBCRG-M08; AMBER study).Org: Osaka University Hospital, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), Nagoya University Hospital,
Abstract
The safety of breast reconstruction: The impact of breast reconstruction surgery on postoperative adjuvant therapy for breast cancer.Org: St. Luke's International Hospital, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, Jikei University School of Medicine, Yokohama City University Medical Center, Yokohama, Japan, Tokyo Medical and Dental University,